Bisphosphonates and atherosclerosis

被引：40

作者：

Ylitalo, R ^{[1
]}

机构：

[1] Univ Tampere, Sch Med, Dept Pharmacol Sci, FIN-33014 Tampere, Finland

[2] Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland

来源：

GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM | 2000年 / 35卷 / 06期

关键词：

atherosclerosis; bisphosphonates; artery; macrophages; calcium; cardiovascular disease;

D O I：

10.1016/S0306-3623(01)00121-5

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Bisphosphonates are used for the treatment of bone resorption, hypercalcemia, osteoporosis and Paget's disease. Etidronate, pamidronate and clodronate also inhibit the development of experimental atherosclerosis without altering serum lipid profile. Bisphosphonates inhibit the arterial calcification, lipid accumulation and fibrosis. They accumulate extensively in arterial walls and suppress macrophages in atheromatous lesions. In macrophage cultures, bisphosphonates inhibit the cellular accumulation and degradation of atherogenic LDL-cholesterol and foam cell formation. Further, they inhibit various enzymes involved in cell signal transduction and cholesterol biosynthesis. Recently, etidronate has been shown to inhibit the thickening of carotid arterial wall even in man. (C) 2002 Elsevier Science Inc. All rights reserved.

引用

页码：287 / 296

页数：10

共 83 条

[31] Alendronate - A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis [J].

Jeal, W ;

Barradell, LB ;

McTavish, D .

DRUGS, 1997, 53 (03) :415-434

[32] Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis [J].

Khan, SA ;

Kanis, JA ;

Vasikaran, S ;

Kline, WF ;

Matuszewski, BK ;

McCloskey, EV ;

Beneton, MNC ;

Gertz, BJ ;

Sciberras, DG ;

Holland, SD ;

Orgee, J ;

Coombes, GM ;

Rogers, SR ;

Porras, AG .

JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (10) :1700-1707

[33] Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes [J].

Koshiyama, H ;

Nakamura, Y ;

Tanaka, S ;

Minamikawa, J .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08) :2793-2796

[34] ATHEROSCLEROSIS - PREVENTION BY AGENTS NOT AFFECTING ABNORMAL LEVELS OF BLOOD-LIPIDS [J].

KRAMSCH, DM ;

ASPEN, AJ ;

ROZLER, LJ .

SCIENCE, 1981, 213 (4515) :1511-1512

[35] EFFECT OF AGENTS INTERFERING WITH SOFT-TISSUE CALCIFICATION AND CELL-PROLIFERATION ON CALCIFIC FIBROUS FATTY PLAQUES IN RABBITS [J].

KRAMSCH, DM ;

CHAN, CT .

CIRCULATION RESEARCH, 1978, 42 (04) :562-571

[36]

LANTTO T, 1989, EUR J NUCL MED, V15, P265

[37] LACK OF EFFECT OF PHENFORMIN, PYRIDINOLCARBAMATE COMBINED WITH A DECALCIFYING AGENT, AND AN ONION-GARLIC MIXTURE ON GROWTH AND NECROSIS OF AORTIC ATHEROSCLEROSIS IN BALLOONED SWINE [J].

LEE, WM ;

LEE, KT .

EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1980, 33 (03) :345-348

[38]

LIN JH, 1991, DRUG METAB DISPOS, V19, P926

[39] Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras [J].

Luckman, SP ;

Hughes, DE ;

Coxon, FP ;

Russell, RGG ;

Rogers, MJ .

JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (04) :581-589

[40] Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein [J].

Luo, GB ;

Ducy, P ;

McKee, MD ;

Pinero, GJ ;

Loyer, E ;

Behringer, RR ;

Karsenty, G .

NATURE, 1997, 386 (6620) :78-81

← 1 2 3 4 5 6 7 8 9 →